April 5: The Week in Cancer News
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
More cancer patients are enrolling in clinical trials, and sentinel node biopsies alone may be adequate for some early-stage breast cancers.
The recently approved immunotherapy Amtagvi uses a patient’s own immune cells to destroy advanced melanoma.
First CAR T-cell therapy approval in chronic lymphocytic leukemia, and Environmental Protection Agency announces a complete ban on asbestos use in manufacturing.
Modified CAR T-cell therapy shows promise in glioblastoma, and an immunotherapy may soon be available as an injection.
Melanoma drug becomes first cell therapy approved to treat a solid tumor, and a new method for treating mesothelioma extended patient survival in a recent trial.
Researchers explore a try-everything approach to precision medicine, and physical activity may help ease cancer pain.
Patients and doctors urge researchers to study lower doses for cancer treatments, and the FDA faces criticism for not issuing a formaldehyde ban in hair straighteners.
Improving fitness linked to lower prostate cancer risk, and a study from Scotland finds no cervical cancer cases in women vaccinated before age 14.
Study shines a light on the differences in outcomes between clinical trial patients with multiple myeloma and those receiving cancer treatment in their community.
Questions about screening for women with dense breast tissue, and the FDA asks drugmakers to add a warning to labels for CAR T-cell therapies.